Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Opportunities
Miguel Vaz, Vítor Silva, Cristina Monteiro, et al.
Clinical Interventions in Aging (2022) Vol. Volume 17, pp. 797-810
Open Access | Times Cited: 125

Showing 1-25 of 125 citing articles:

Aducanumab for the treatment of Alzheimer's disease: a systematic review
Afroza Rahman, Md. Anwar Hossen, Mirza Farhana Iqbal Chowdhury, et al.
Psychogeriatrics (2023) Vol. 23, Iss. 3, pp. 512-522
Open Access | Times Cited: 58
Alzheimer's disease current therapies, novel drug delivery systems and future directions for better disease management
Baljinder Singh, Candace M. Day, Sadikalmahdi Abdella, et al.
Journal of Controlled Release (2024) Vol. 367, pp. 402-424
Open Access | Times Cited: 56
Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
Francesca R. Buccellato, Marianna D’Anca, Gianluca Martino Tartaglia, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 18, pp. 13900-13900
Open Access | Times Cited: 48
Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications
Sarah J. Doran, Russell P. Sawyer
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 30
Review on anti-alzheimer drug development: approaches, challenges and perspectives
Abdallah E. Abdallah
RSC Advances (2024) Vol. 14, Iss. 16, pp. 11057-11088
Open Access | Times Cited: 20
Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer’s Disease and Identifying Promising Drug Targets
Zdeněk Fišar
Biomolecules (2022) Vol. 12, Iss. 11, pp. 1676-1676
Open Access | Times Cited: 53
Basic information about memantine and its treatment of Alzheimer's disease and other clinical applications
Bin‐Can Tang, Ya‐Ting Wang, Jie Ren
Ibrain (2023) Vol. 9, Iss. 3, pp. 340-348
Open Access | Times Cited: 43
Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Ernesto Fedele
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14499-14499
Open Access | Times Cited: 36
Antibody-Mediated Clearance of Brain Amyloid-β: Mechanisms of Action, Effects of Natural and Monoclonal Anti-Aβ Antibodies, and Downstream Effects
David A. Loeffler
Journal of Alzheimer s Disease Reports (2023) Vol. 7, Iss. 1, pp. 873-899
Open Access | Times Cited: 34
Intranasal Drug Delivery by Nanotechnology: Advances in and Challenges for Alzheimer’s Disease Management
Sayali Dighe, Sunil Jog, Munira Momin, et al.
Pharmaceutics (2023) Vol. 16, Iss. 1, pp. 58-58
Open Access | Times Cited: 26
Unveiling the impact of aging on BBB and Alzheimer's disease: Factors and therapeutic implications
Niraj Kumar Jha, Niraj Kumar Jha, Mohana Vamsi Nuli, et al.
Ageing Research Reviews (2024) Vol. 98, pp. 102224-102224
Closed Access | Times Cited: 14
Proposed mechanisms of tau: relationships to traumatic brain injury, Alzheimer’s disease, and epilepsy
Samantha P. Martin, Beth A. Leeman-Markowski
Frontiers in Neurology (2024) Vol. 14
Open Access | Times Cited: 9
Evaluation of the Sporadic Anti-Alzheimer’s Activity of Purpurin Using In Silico, In Vitro, and In Vivo Approaches
Kajol Rustage, Nitish Rai, Saurabh K. Sinha, et al.
Molecular Neurobiology (2025)
Closed Access | Times Cited: 1
New Possibilities in the Therapeutic Approach to Alzheimer’s Disease
Julia Doroszkiewicz, Barbara Mroczko
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 8902-8902
Open Access | Times Cited: 29
Photobiomodulation in Alzheimer’s Disease—A Complementary Method to State-of-the-Art Pharmaceutical Formulations and Nanomedicine?
Laura Marinela Ailioaie, Constantin Ailioaie, Gerhard Litscher
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 916-916
Open Access | Times Cited: 22
Small molecule targeting long noncoding RNA GAS5 administered intranasally improves neuronal insulin signaling and decreases neuroinflammation in an aged mouse model
Rekha Patel, Ashley Lui, Charles E. Hudson, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 21
Design of a new potent Alzheimer's disease inhibitor based on QSAR, molecular docking and molecular dynamics investigations
Meriem Khedraoui, Hassan Nour, Imane Yamari, et al.
Chemical Physics Impact (2023) Vol. 7, pp. 100361-100361
Open Access | Times Cited: 20
Digital Health Technologies for Alzheimer’s Disease and Related Dementias: Initial Results from a Landscape Analysis and Community Collaborative Effort
S Lott, Emmanuel Streel, Shelby L. Bachman, et al.
The Journal of Prevention of Alzheimer s Disease (2024)
Closed Access | Times Cited: 9
Symptoms and conventional treatments of Alzheimer's disease
Mehul R. Chorawala, Aayushi C. Shah, Aanshi J. Pandya, et al.
Elsevier eBooks (2024), pp. 213-234
Closed Access | Times Cited: 8
Nanocarriers-mediated nose-to-brain drug delivery: A novel approach for the management of Alzheimer’s disease
Abhishek Sonwani, Anchal Pathak, Keerti Jain
Journal of Drug Delivery Science and Technology (2024) Vol. 98, pp. 105855-105855
Closed Access | Times Cited: 8
Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Amin Mahmood Thawabteh, Aseel Wasel Ghanem, Sara AbuMadi, et al.
Molecules (2024) Vol. 29, Iss. 21, pp. 5131-5131
Open Access | Times Cited: 8
Alzheimer's disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges
Saeid Safiri, Amir Ghaffari Jolfayi, Asra Fazlollahi, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 8
More failure with solanezumab – this time in preclinical Alzheimer’s disease
Sheila A Doggrell
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 3, pp. 119-123
Closed Access | Times Cited: 7
Evidence of disturbed insulin signaling in animal models of Alzheimer’s disease
Suélen Santos Alves, Gabriel Servilha‐Menezes, Letícia Rossi, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 152, pp. 105326-105326
Closed Access | Times Cited: 15
Tau Protein and Tauopathies: Exploring Tau Protein‐Protein and Microtubule Interactions, Cross‐Interactions and Therapeutic Strategies.
Davide di Lorenzo
ChemMedChem (2024) Vol. 19, Iss. 21
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top